Form 10-Q April 29, 2014	
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549	
FORM 10-Q	
[X] QUARTERLY REPORT PURSUANT TO SECTION OF THE SECURITIES EXCHANGE ACT OF 1934	13 OR 15(d)
For the quarterly period ended March 31, 2014 OR	
[] TRANSITION REPORT PURSUANT TO SECTION OF THE SECURITIES EXCHANGE ACT OF 1934	13 OR 15(d)
For the transition period from to	
Commission file number 1-11353	
LABORATORY CORPORATION OF AMERICA HOLDINGS	
(Exact name of registrant as specified in its charter) Delaware	13-3757370
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
358 South Main Street,	
Burlington, North Carolina (Address of principal executive offices)	27215 (Zip Code)
(Registrant's telephone number, including area code) 336-2	229-1127
Indicate by check mark whether the registrant (1) has filed Securities Exchange Act of 1934 during the preceding 12 required to file such reports) and (2) has been subject to su	
Indicate by check mark whether the registrant has submitted any, every Interactive Data File required to be submitted at (paragraph 232.405 of this chapter) during the preceding 1 required to submit and post such files). Yes [X] No []	nd posted pursuant to Rule 405 of Regulation S-T
Indicate by check mark whether the registrant is a large accornance a smaller reporting company. See the definitions of "large company" in Rule 12b-2 of the Exchange Act.	celerated filer, an accelerated filer, a non-accelerated filer, ge accelerated filer," "accelerated filer," and "smaller reporting
Large accelerated filer [X]	Accelerated Filer []
Non-accelerated filer [] (Do not check if a smaller reporting company)	Smaller reporting company []

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [] No [X].

The number of shares outstanding of the issuer's common stock is 84.8 million shares, net of treasury stock as of April 24, 2014.

INDEX

PART I. FINANCIAL INFORMATION

Item	1	Financ	rial	Statements:
пеш	1.	гшаш		Statements.

	Condensed Consolidated Balance Sheets March 31, 2014 and December 31, 2013	2
	Condensed Consolidated Statements of Operations Three months ended March 31, 2014 and 2013	<u>3</u>
	Condensed Consolidated Statements of Comprehensive Earnings Three months ended March 31, 2014 and 2013	<u>4</u>
	Condensed Consolidated Statements of Changes in Shareholders' Equity Three months ended March 31, 2014 and 2013	<u>5</u>
	Condensed Consolidated Statements of Cash Flows Three months ended March 31, 2014 and 2013	<u>6</u>
	Notes to Unaudited Condensed Consolidated Financial Statements	7
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	<u>20</u>
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	<u>27</u>
Item 4.	Controls and Procedures	<u>28</u>
PART II	. OTHER INFORMATION	
Item 1.	<u>Legal Proceedings</u>	<u>29</u>
Item 1A.	. Risk Factors	<u>29</u>
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	<u>29</u>
Item 6.	<u>Exhibits</u>	<u>29</u>
1		

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS

(in millions)
(unaudited)

	March 31, 2014	December 31, 2013	,
ASSETS			
Current assets:			
Cash and cash equivalents	\$338.9	\$404.0	
Accounts receivable, net of allowance for doubtful accounts of \$200.8 and \$198.3 at March 31, 2014 and December 31, 2013, respectively	822.0	784.7	
Supplies inventories	134.8	136.5	
Prepaid expenses and other	125.2	106.9	
Total current assets	1,420.9	1,432.1	
Property, plant and equipment, net	733.1	707.4	
Goodwill, net	3,067.1	3,022.8	
Intangible assets, net	1,538.4	1,572.0	
Joint venture partnerships and equity method investments	87.3	88.5	
Other assets, net	145.6	143.1	
Total assets	\$6,992.4	\$6,965.9	
LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities:			
Accounts payable	\$281.9	\$304.5	
Accrued expenses and other	358.0	310.0	
Deferred income taxes	8.4	9.9	
Short-term borrowings and current portion of long-term debt	105.3	111.3	
Total current liabilities	753.6	735.7	
Long-term debt, less current portion	2,903.0	2,889.1	
Deferred income taxes and other tax liabilities	561.9	563.9	
Other liabilities	254.0	266.5	
Total liabilities	4,472.5	4,455.2	
Commitments and contingent liabilities			
Noncontrolling interest	18.6	19.4	
Shareholders' equity:			
Common stock, 84.8 and 85.7 shares outstanding at March 31, 2014 and	10.4	10.5	
December 31, 2013, respectively	10.4	10.3	
Additional paid-in capital		_	
Retained earnings	3,408.9	3,373.5	
Less common stock held in treasury	(963.5) (958.9)
Accumulated other comprehensive income	45.5	66.2	
Total shareholders' equity	2,501.3	2,491.3	
Total liabilities and shareholders' equity	\$6,992.4	\$6,965.9	

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in millions, except per share data) (unaudited)

	Three Mon	Three Months Ended		
	March 31,			
	2014	2013		
Net sales	\$1,430.7	\$1,440.9		
Cost of sales	913.9	868.7		
Gross profit	516.8	572.2		
Selling, general and administrative expenses	284.9	283.2		
Amortization of intangibles and other assets	21.0	19.5		
Restructuring and other special charges	7.6	7.5		
Operating income	203.3	262.0		
Other income (expenses):				
Interest expense	(25.7) (24.5)	
Equity method income, net	3.0	4.3		
Investment income	0.2	0.2		
Other, net	6.9	(0.6)	
Earnings before income taxes	187.7	241.4		
Provision for income taxes	74.2	93.8		
Net earnings	113.5	147.6		
Less: Net earnings attributable to the noncontrolling interest	(0.4) (0.4)	
Net earnings attributable to Laboratory Corporation of America Holdings	\$113.1	\$147.2		
Basic earnings per common share	\$1.33	\$1.58		
Diluted earnings per common share	\$1.31	\$1.56		

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE EARNINGS (in millions, except per share data) (unaudited)

		Three Months Ended March 31,		
	2014	2013		
Net earnings	\$113.5	\$147.6		
Foreign currency translation adjustments	(36.0) (27.7)	
Net benefit plan adjustments	2.3	3.2		
Investment adjustments	(0.6) —		
Other comprehensive loss before tax	(34.3) (24.5)	
Provision for income tax related to items of comprehensive earnings	13.6	8.9		
Other comprehensive loss, net of tax	(20.7) (15.6)	
Comprehensive earnings	92.8	132.0		
Less: Net earnings attributable to the noncontrolling interest	(0.4) (0.4)	
Comprehensive earnings attributable to Laboratory Corporation of America Holdings	\$92.4	\$131.6		

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY

(in millions)
(unaudited)

	Common Stock	Additional Paid-in Capital	Retained Earnings	Treasury Stock	Accumulated Other Comprehensive Income	Total Shareholde Equity	ers'
BALANCE AT DECEMBER 31, 2012	\$11.3	\$—	\$3,588.5	\$(951.8	\$69.4	\$2,717.4	
Net earnings attributable to Laboratory Corporation of America Holdings		_	147.2	_	_	147.2	
Other comprehensive earnings, net of tax	_	_	_	_	(15.6)	(15.6)
Issuance of common stock under employee stock plans	_	28.8	_	_	_	28.8	
Surrender of restricted stock and performance share awards	_	_	_	(2.4) —	(2.4)
Conversion of zero-coupon convertible debt	_	3.1	_	_	_	3.1	
Stock compensation	_	11.3	_			11.3	
Income tax benefit from stock options exercised	_	2.4	_	_	_	2.4	
Purchase of common stock	(0.1)	(45.6)	(68.2)	_		(113.9)
BALANCE AT MARCH 31, 2013	,	\$—	\$3,667.5	\$(954.2	\$53.8	\$2,778.3	,
BALANCE AT DECEMBER 31, 2013	\$10.5	\$—	\$3,373.5	\$(958.9) \$66.2	\$2,491.3	
Net earnings attributable to Laboratory Corporation of America Holdings	a —	_	113.1	_	_	113.1	
Other comprehensive earnings, net of tax	_	_	_	_	(20.7)	(20.7)
Issuance of common stock under employee stock plans	_	16.4	_	_	_	16.4	
Surrender of restricted stock and performance share awards	_	_	_	(4.6) —	(4.6)
Conversion of zero-coupon convertible debt	_	1.2	_	_	_	1.2	
Stock compensation	_	11.7			_	11.7	
Income tax benefit from stock options exercised	_	0.6	_	_	_	0.6	
Purchase of common stock BALANCE AT MARCH 31, 2014		(29.9) \$—	(77.7) \$3,408.9	 \$(963.5		(107.7 \$2,501.3)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

INDEX

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in millions) (unaudited)

	Three Months Ended		
	March 31,		
	2014	2013	
CASH FLOWS FROM OPERATING ACTIVITIES:			
Net earnings	\$113.5	\$147.6	
Adjustments to reconcile net earnings to net cash provided by operating activities:			
Depreciation and amortization	60.7	55.5	
Stock compensation	11.7	11.3	
(Gain)/loss on sale of assets	(7.1) 0.2	
Accrued interest on zero-coupon subordinated notes	0.5	0.6	
Earnings in excess of distributions from equity method investments	(1.3) (0.6)
Deferred income taxes	10.1	10.3	
Change in assets and liabilities (net of effects of acquisitions):			